| Literature DB >> 9544206 |
S J Hays1, B W Caprathe, J L Gilmore, N Amin, M R Emmerling, W Michael, R Nadimpalli, R Nath, K J Raser, D Stafford, D Watson, K Wang, J C Jaen.
Abstract
A series of 2-amino-4H-3,1-benzoxazin-4-ones have been synthesized and evaluated as inhibitors of the complement enzyme C1r. C1r is a serine protease at the beginning of the complement cascade, and complement activation by beta-amyloid may represent a major contributing pathway to the neuropathology of Alzheimer's disease. Compounds such as 7-chloro-2-[(2-iodophenyl)-amino]benz[d][1,3]oxazin-4-one (32) and 7-methyl-2-[(2-iodophenyl)amino]benz[d][1,3]oxazin-4-one (37) show improved potency compared to the reference compound FUT-175. Many of these active compounds also possess increased selectivity for C1r compared to trypsin and enhanced hydrolytic stability relative to 2-(2-iodophenyl)-4H-3,1-benzoxazin-4-one (1).Entities:
Mesh:
Substances:
Year: 1998 PMID: 9544206 DOI: 10.1021/jm970394d
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446